Epilepsy is a heterogeneous condition requiring individualized treatment, based largely on a patient’s seizure syndrome and seizure type. Epilepsy patients also differ widely in their responses to treatment with antiepileptic drugs (AEDs) and often are treatment-refractory. As a result, neurologists must consider many factors when selecting among the numerous first-, second-, and third-generation AEDs currently available, and make adjustments—in dosing, or by adding and switching—throughout a patients’ disease course to achieve optimal seizure control. Understanding the many decision points neurologists face in the treatment of epilepsy provides important context about the complex market that developers of investigational AEDs will enter.
How is epilepsy being treated in the United States today, and what are the factors behind those treatment decisions? The Epilepsy Current Treatment Overview provides a synopsis of current treatment goals, key therapies, and medical practice in the G7 markets. The detailed, expanded analysis in Epilepsy Current Treatment (US) offers a snapshot of how U.S. neurologists are currently managing their epilepsy patients as well as insight into the factors driving such prescribing habits. This new Current Treatment offering provides deep insights, with real-world evidence wherever possible.